2013 ESH/ESC Guidelines for the management of arterial hypertension

Abstract

Table of Contents Introduction Principles New aspects Epidemiological aspects Relationship of blood pressure to cardiovascular and renal damage Definition and classification of hypertension Prevalence of hypertension Hypertension and total cardiovascular risk Assessment of total cardiovascular risk Limitations Summary of recommendations on total cardiovascular risk assessment Diagnostic evaluation Bood pressure measurement Office or clinic blood pressure Out-of-office blood pressure White-coat (or isolated office) hypertension and masked (or isolated ambulatory) hypertension Clinical indications for out-of-office blood pressure Blood pressure during exercise and laboratory stress Central blood pressure Medical history Physical examination Summary of recommendations on blood pressure measurement, history, and physical examination Laboratory investigations Genetics Searching for asymptomatic organ damage Heart Blood vessels Kidney Fundoscopy Brain Clinical value and limitations Summary of recommendations on the search for asymptomatic organ damage, cardiovascular disease, and chronic kidney disease Searching for secondary forms of hypertension Treatment approach Evidence favouring therapeutic reduction of high blood pressure When to initiate antihypertensive drug treatment Recommendations of previous Guidelines Grade 2 and 3 hypertension and high-risk grade 1 hypertension Low-to-moderate risk, grade 1 hypertension Isolated systolic hypertension in youth Grade 1 hypertension in the elderly High normal blood pressure Summary of recommendations on initiation of antihypertensive drug treatment Blood pressure treatment targets Recommendations of previous Guidelines Low-to-moderate risk hypertensive patients Hypertension in the elderly High-risk patients The ‘lower the better’ vs. the J-shaped curve hypothesis Evidence on target blood pressure from organ damage studies Clinic vs. home and ambulatory blood pressure targets Summary of recommendations on blood pressure targets in hypertensive patients Treatment strategies Lifestyle changes Salt restriction Moderation of alcohol consumption Other dietary changes Weight reduction Regular physical exercise Smoking cessation Summary of recommendations on adoption of lifestyle changes Pharmacological therapy Choice of antihypertensive drugs Monotherapy and combination therapy Summary of recommendations on treatment strategies and choice of drugs Treatment strategies in special conditions White-coat hypertension Masked hypertension Summary of recommendations on treatment strategies in white-coat and masked hypertension Elderly Summary of recommendations on antihypertensive treatment strategies in the elderly Young adults Women Oral contraceptives Hormone replacement therapy Pregnancy Long-term cardiovascular consequences in gestational hypertension Summary of recommendations on treatment strategies in hypertensive women Diabetes mellitus Summary of recommendations on treatment strategies in patients with diabetes Metabolic syndrome Summary of recommendations on treatment strategies in hypertensive patients with metabolic syndrome Obstructive sleep apnoea Diabetic and non-diabetic nephropathy Summary of recommendations on therapeutic strategies in hypertensive patients with nephropathy Chronic kidney disease stage 5D Cerebrovascular disease Acute stroke Previous stroke or transient ischaemic attack Cognitive dysfunction and white matter lesions Summary of recommendations on therapeutic strategies in hypertensive patients with cerebrovascular disease Heart disease Coronary heart disease Heart failure Atrial fibrillation Left ventricular hypertrophy Summary of recommendations on therapeutic strategies in hypertensive patients with heart disease Atherosclerosis, arteriosclerosis, and peripheral artery disease Carotid atherosclerosis Increased arterial stiffness Peripheral artery disease Summary of recommendations on therapeutic strategies in hypertensive patients with atherosclerosis, arteriosclerosis, and peripheral artery disease Sexual dysfunction Resistant hypertension Carotid baroreceptor stimulation Renal denervation Other invasive approaches Follow-up in resistant hypertension Summary of recommendations on therapeutic strategies in patients with resistant hypertension Malignant hypertension Hypertensive emergencies and urgencies Perioperative management of hypertension Renovascular hypertension Primary aldosteronism Treatment of associated risk factors Lipid-lowering agents Antiplatelet therapy Treatment of hyperglycaemia Summary of recommendations on treatment of risk factors associated with hypertension Follow-up Follow-up of hypertensive patients Follow-up of subjects with high normal blood pressure and white-coat hypertension Elevated blood pressure at control visits Continued search for asymptomatic organ damage Can antihypertensive medications be reduced or stopped? Improvement of blood pressure control in hypertension Hypertension disease management Team approach in disease management Mode of care delivery The role of information and communication technologies 53 Gaps in evidence and need for future trials Appendix 1 Appendix 2 Acknowledgments References 1. INTRODUCTION 1.1 Principles The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007 [1,2]. Publication of a new document 6 years after the previous one was felt to be timely because, over this period, important studies have been conducted and many new results have been published on both the diagnosis and treatment of individuals with an elevated blood pressure (BP), making refinements, modifications and expansion of the previous recommendations necessary. The 2013 ESH/ESC guidelines continue to adhere to some fundamental principles that inspired the 2003 and 2007 guidelines, namely (i) to base recommendations on properly conducted studies identified from an extensive review of the literature, (ii) to consider, as the highest priority, data from randomized, controlled trials (RCTs) and their meta-analyses, but not to disregard—particularly when dealing with diagnostic aspects—the results of observational and other studies of appropriate scientific calibre, and (iii) to grade the level of scientific evidence and the strength of recommendations on major diagnostic and treatment issues as in European guidelines on other diseases, according to ESC recommendations (Tables 1 and 2). While it was not done in the 2003 and 2007 guidelines, providing the recommendation class and the level of evidence is now regarded as important for providing interested readers with a standard approach, by which to compare the state of knowledge across different fields of medicine. It was also thought that this could more effectively alert physicians on recommendations that are based on the opinions of the experts rather than on evidence. This is not uncommon in medicine because, for a great part of daily medical practice, no good science is available and recommendations must therefore stem from common sense and personal clinical experience, both of which can be fallible. When appropriately recognized, this can avoid guidelines being perceived as prescriptive and favour the performance of studies where opinion prevails and evidence is lacking. A fourth principle, in line with its educational purpose, is to provide a large number of tables and a set of concise recommendations that could be easily and rapidly consulted by physicians in their routine practice.TABLE 1: Classes of recommendationsTABLE 2: Levels of EvidenceThe European members of the Task Force in charge of the 2013 guidelines on hypertension have been appointed by the ESH and ESC, based on their recognized expertise and absence of major conflicts of interest [their declaration of interest forms can be found on the ESC website (www.escardio.org/guidelines) and ESH website (www.eshonline.org)]. Each member was assigned a specific writing task, which was reviewed by three co-ordinators and then by two chairmen, one appointed by ESH and another by ESC. The text was finalized over approximately 18 months, during which the Task Force members met collectively several times and corresponded intensively with one another between meetings. Before publication, the document was also assessed twice by 42 European reviewers, half selected by ESH and half by ESC. It can thus be confidently stated that the recommendations issued by the 2013 ESH/ESC guidelines on hypertension largely reflect the state of the art on hypertension, as viewed by scientists and physicians in Europe. Expenses for meetings and the remaining work have been shared by ESH and ESC. 1.2 New aspects Because of new evidence on several diagnostic and therapeutic aspects of hypertension, the present guidelines differ in many respects from the previous ones [2]. Some of the most important differences are listed below: Epidemiological data on hypertension and control in Europe. of the value of home blood pressure and of its role for diagnosis and management of hypertension, to ambulatory blood pressure of the of white-coat hypertension and masked on of cardiovascular risk asymptomatic organ damage and clinical for total risk of the of asymptomatic blood and of the risk of and target in Hypertension in of antihypertensive and no drug treatment of high normal for and target systolic blood pressure in both and risk approach to for New therapeutic for target on therapeutic strategies in special recommendations on treatment of hypertension in the treatment of to resistant hypertension and new treatment Increased to New approaches to chronic management of hypertensive Relationship of blood pressure to cardiovascular and renal damage The between and and renal been in a large number of observational studies The in in the 2003 and 2007 ESH/ESC guidelines can be as Office an with the of several heart failure and peripheral artery disease as as of renal disease This is at and in The with from high to of for and for to be a of than after the of years and in elderly individuals pressure between and been to have a role This is also by the high risk by patients with an elevated and a normal or systolic hypertension A with is also by out-of-office as by and The between and and is by the of other risk Metabolic risk factors are more common when is high than when it is Definition and classification of hypertension The between and and renal the between and hypertension when based on This is more because, in the and have a practice, are both to the diagnostic approach and to the The classification is from the 2003 and 2007 ESH/ESC guidelines Hypertension is as based on the evidence from that in patients with are and The classification is in and elderly different based on are in and for data from trials are not on classification in and according to their and can be found in the on the evaluation and treatment of high in and and classification of blood pressure Prevalence of hypertension data are available on the of hypertension and the of in different European the of hypertension to be of the with a with also to be differences in the across with no changes in the to the of results and the of a of hypertension been is a good hypertension is by the most important of this A between of hypertension and for stroke been The and of stroke in have been by of European a in to European which a in from stroke Hypertension and total cardiovascular risk a hypertension guidelines on as the or the need the the ESC, ESH and European Society recommendations on of heart disease in clinical and that of be to of total (or This approach is now and been the 2003 and 2007 ESH/ESC guidelines for the management of arterial hypertension [1,2]. The is based on the that a of the hypertensive an of with the risk when and other risk factors to a total risk that is than the of its in high-risk antihypertensive treatment strategies and of of drug and as as other be different from to be in is evidence in high-risk control is more and more the combination of antihypertensive drugs with other as The therapeutic approach total risk in to in to of the management of Assessment of total cardiovascular risk of total risk is in of as with of cardiovascular disease or with elevated risk of the total risk is high or for a large number of patients with hypertension not to of the and the of at high or high risk the of to total risk, as to be to the therapeutic approach have been for total risk and limitations have been reviewed The been based on large European The the risk of from disease over years based on total and The of the for which been done for European the two of are one for high-risk and one for The of as Heart is to also for the of on total The and their can in risk assessment and management but must be in the of the knowledge and experience, with to the that total risk is associated with clinical when with other strategies not been be than in the subjects and with the risk associated with is in subjects than in individuals and from with elevated an not the diagnostic for with and with a history of the of years in and years in total risk is as the risk of from Because of its on in total risk can be in the of high with risk this to a high-risk years treatment be by of risk or by heart and A is available in the European on in Clinical which is when been to of asymptomatic in several in the which the risk that by the of risk A is to for asymptomatic where evidence for the risk of clinical is more than a guidelines for the management of hypertension and 2003 Society of Hypertension Guidelines and the 2003 and 2007 ESH/ESC have risk in different based on risk asymptomatic and of or chronic kidney disease as also done by the ESC guidelines The classification in high and high risk is in the guidelines and to the risk of as by the ESC guidelines The factors on which the is based are in Table 1: of total risk in of high and high risk according to and and of asymptomatic stage or with a high normal but a out-of-office have a risk in the hypertension with a high but normal out-of-office is no or have risk than hypertension for the than for of total risk in Limitations available for risk assessment have limitations that must be The of in of risk is on the damage is based on available limitations also be that the of total risk is to the of to that to grade in to the of risk is by or to a which treatment is It be in that to high total risk is as as the of a value to this and no at is a of on total risk It is that adults are to high-risk when have more than one major risk and a in many elderly a high total risk level being at risk to their The consequences are that most are in is and is to subjects at high risk the in the absence of their to an risk to a high and risk in with of their Summary of recommendations on total cardiovascular risk assessment cardiovascular risk The evaluation of a with hypertension (i) the diagnosis of hypertension, (ii) of secondary hypertension, and (iii) risk, and clinical This for measurement, medical history history, physical laboratory investigations and diagnostic Some of the investigations are in in specific Bood pressure measurement Office or clinic blood pressure can no be a in not or are be according to and their be in a laboratory of at the is and and be to the the of a and between which been to an risk the with the be A is by one a between with measurement, it could be to elderly patients and in other conditions in which be or it is that be 1 and 3 after of the as a reduction in of or in of 3 of been to a for and of in the with the in an isolated providing information be as a to and to by or be associated with measurement of heart heart or in several hypertension for are in Table Office blood pressure Out-of-office blood pressure The major of out-of-office is that it a large number of from the medical which a more assessment of than Out-of-office is assessed by or by A principles and for the two of in to recommendations for measurement The be to the with and in of appropriate medical of the results that the of out-of-office is good for and but for the and for more and and provide different information on the and risk and the two thus be regarded as rather than or The between with and is to Office is than ambulatory and home and the as for the of hypertension for home and ambulatory according to the ESH on are in Table have been and according to and be properly and at 6 The can be on of hypertension by and out-of-office blood pressure blood pressure aspects A number of aspects have been by the ESH on Blood is with the a on the for a period, that it information on during daily and at during the of of the the between the and from measurement by the not be than the of a the be and The is to in normal but to from exercise at the of to and and the with the at heart The is to provide information in a on and that in to the times of drug and and from clinical practice, are at during the and between be the of It be that be at the during the and The are to a and a of can be of during and be or the be The of and the of have been to are is not and be It is that not be when the is and blood pressure to the and are the most in clinical and can be from the on the of the times of and to is to in which the and differ from to It for been that from to and from to 6 with the and but other have been as from to and from 1 to 6 the of different measurement during the and the and to for it is that be for the between or to the of the to avoid of The the between and during the as the of a normal in a it is that the of a of of be as an to subjects as more have been absence of for and women been in a number of but other of an to exercise have also been the of at exercise is to arterial stiffness and and is in women than in and in than in individuals not have that an of during exercise the of hypertension in of at exercise to future hypertension is not of a number of as of of and is no on the of exercise with as after for and other as in as in hypertensive patients the results on the of exercise are not which be to the that the two of in during It is that the is a reduction of during with changes in and or not the arterial is an of at on subjects and in hypertensive patients with of an a the of normal hypertension can be an for of its with masked hypertension the other when hypertension is associated with dysfunction and of the of exercise be a during exercise a as in individuals in patients with disease or with heart failure in a exercise systolic the results the clinical of during exercise for diagnostic and in patients with exercise is as a exercise and data and an A number of stress have been to stress and a of or laboratory stress in not reflect stress and are not have and between to the are results on the of the to with future hypertension are not the is A that to stress an on future risk of elevated hypertension, ventricular atherosclerosis and clinical The results that during stress are not Central blood pressure The measurement of in hypertensive patients interest of both its value for and the of antihypertensive with The arterial pressure is a of the pressure by ventricular and a It be at the in the it the on kidney and large The of can be the as the between the and systolic as a of the for heart to the of and pressure the arterial systolic and be different from the years several and have been to systolic or pressure from pressure have been reviewed in an document studies in the that and by of and in patients with A in several the value of was or not in most studies the guidelines, previous ones the measurement of and is of great interest for in and more is their routine clinical The be in the in some of individuals at the level be to high of the pressure is normal Medical history The medical history the of the diagnosis of arterial hypertension, and and and antihypertensive be to indications of secondary of Women be Hypertension an risk of renal and heart when are a history of be in to assessment of risk, as clinical or a history of heart or heart disease, with an on stroke and transient ischaemic attack A history of the and of kidney and evidence for be A history of hypertension is an important of to hypertension and and on and medical history are in Table and medical Physical examination Physical examination to or the diagnosis of hypertension, for secondary of hypertension and risk be as in and be to the diagnosis of at one to be at both and differences between the two in in investigations of patients of the heart and renal renal on the of the and be with the and and heart be the is at heart an risk of heart the of on physical examination are in Table Physical examination for secondary hypertension, organ damage and Summary of recommendations on blood pressure history, and physical examination pressure history, and physical on Blood pressure history, and physical Laboratory investigations Laboratory investigations are at providing evidence for the of risk for secondary hypertension and for the absence or of from the most to the more on laboratory investigations are in Table Laboratory Genetics A history is a in hypertensive patients with the to between and in the of studies and been for ambulatory forms of hypertension have been as syndrome and where a the of hypertension and the treatment hypertension is a with a studies and their to a total of which are associated with systolic to risk for Searching for asymptomatic organ damage to the of asymptomatic as an stage in the of disease, and as a of risk, of organ be by appropriate It be that a large of evidence is now available on the role of asymptomatic in the risk of individuals with and high The that of of and can of is a in favour of assessment of in daily clinical more data from studies in different be It is also that the risk as the number of Heart A be part of the routine assessment of hypertensive in is by the the or been found in observational studies and clinical trials to be an of the is at in patients over years of can also be to of ventricular or which more risk and is when and ischaemic are Atrial fibrillation is a and common of in hypertensive patients of fibrillation the of by appropriate therapy not from is more than in and is to and renal risk It therefore in a more of risk and in therapy evaluation of the in hypertensive patients of and and While ventricular for or the or of is according to the Society of the between and risk is of for women and for are for of of for in which to the of or been can be in and patients in to to and avoid of It been that the is to by to the and that different for and women be by could in subjects and in ones with with and with normal an of but is the of risk Hypertension is associated with of and as dysfunction is associated with and can of heart when is normal failure with The can and heart failure and but is not to the hypertensive clinical and to recommendations it therefore be with of the of the is of hypertensive heart disease the is reduced more than the and of dysfunction is based on of and and the between and and This is an important of in a large The of and of are on and on The is to an of The value of is recognized in the hypertensive and is associated with risk, of and in hypertensive patients of can provide information and is a for the diagnosis of Left is assessed by its or been to be an of heart fibrillation and ischaemic stroke and for hypertensive heart disease for are in Table The most for in hypertension is to by that the on of and are largely largely from control with the for by the Society of and the European of are in the of for from large in different be available for in the assessment of and in patients with on and systolic can and to systolic dysfunction of hypertensive patients assessment of systolic in hypertensive heart disease not information to at in the of a normal clinical practice, be in hypertensive patients in different clinical and with different in hypertensive patients at total risk, it the risk evaluation by by in hypertensive patients with evidence of it more the hypertrophy and its and in hypertensive patients with it to It is that assessment of and be of diagnostic value in most patients with hypertension and be in hypertensive patients at the a or more on and be for assessment of and when is not and when of have therapeutic consequences are for diagnosis of in hypertensive patients with This is hypertension the of exercise and exercise a normal and an value in patients of When the exercise is or an of as stress or stress is for a of are specific for assessed artery are found with normal associated with disease The of of and on the artery been to from isolated damage A been to have an value in hypertension Blood vessels Carotid examination of the with measurement of the of been to the of both stroke and of risk factors This both for the value at the and for the value at the level of the common artery The between and is a one and a for high risk is rather a been as a of in the 2007 Guidelines the value for high risk was in the elderly patients of the and in the patients of the European on and of a can be identified by an or by a in of or of the value a value for of a and to other for and patients another risk in the A review that the value of be found in asymptomatic individuals at